Tirzepatide long-term side effects: is it safe over time?

10 min read

Written by: 

John Wood

Reviewed by: 

Patricia Weiser, PharmD

Updated:  Nov 17, 2026

Trusted source badge

Reviewed By

Patricia Weiser, PharmD

Patricia Weiser, PharmD, is a licensed pharmacist with more than a decade of clinical experience.

View bio

Key takeaways

  • Digestive issues are among tirzepatide’s common side effects and may improve once your dose stops going up. Constipation, reflux, fatigue, and hair loss can also come up during treatment.

  • Serious risks include gallbladder disease, pancreatitis, kidney injury from dehydration, low blood sugar, and a thyroid tumor warning based on rodent studies. The FDA has also announced a new warning for all GLP-1–based medications about a rare eye condition that can cause permanent vision loss.

  • People who stopped tirzepatide in a clinical trial regained a substantial amount of weight on average, so talk with your healthcare provider before changing or stopping your dose.

  • One trial has followed people on the medication for about four years, and another found no new safety concerns over three years, but tirzepatide’s effects over decades, including cancer risk, are still unknown.

Here's what we'll cover

Here's what we'll cover

Key takeaways

  • Digestive issues are among tirzepatide’s common side effects and may improve once your dose stops going up. Constipation, reflux, fatigue, and hair loss can also come up during treatment.

  • Serious risks include gallbladder disease, pancreatitis, kidney injury from dehydration, low blood sugar, and a thyroid tumor warning based on rodent studies. The FDA has also announced a new warning for all GLP-1–based medications about a rare eye condition that can cause permanent vision loss.

  • People who stopped tirzepatide in a clinical trial regained a substantial amount of weight on average, so talk with your healthcare provider before changing or stopping your dose.

  • One trial has followed people on the medication for about four years, and another found no new safety concerns over three years, but tirzepatide’s effects over decades, including cancer risk, are still unknown.

If you take tirzepatide, you’re most likely to notice digestive symptoms, which tend to ease once your dose stops increasing. Serious tirzepatide long-term side effects are less common and include gallbladder problems, pancreatitis, dehydration-related kidney injury, low blood sugar when paired with some diabetes medications, a thyroid tumor warning from rodent studies, and a warning about a rare eye condition.

The US Food and Drug Administration (FDA) first approved tirzepatide as Mounjaro in 2022 for type 2 diabetes, and then in 2023 as Zepbound for chronic weight management. Since then, the agency has continued to update both labels, including safety warnings. Some trials have now followed people on tirzepatide for 3–4 years, and a three-year trial in adults with obesity and prediabetes found no new safety concerns.

Knowing which side effects can show up with ongoing use and which symptoms need quick care can help you and your healthcare provider plan treatment with Zepbound or Mounjaro.

What are the long-term side effects of tirzepatide?

When people ask about long-term side effects of a medication, they’re usually asking about one of two things. The first is side effects that become more likely the longer you take it. The second is side effects that don’t go away over time, whether or not you stop taking it.

The most common side effects of tirzepatide are digestive problems, such as nausea, diarrhea, vomiting, and constipation. These side effects usually happen during the first few months of treatment, while the dose is still going up, and often improve over time. Other side effects reported more commonly with tirzepatide than placebo include injection site reactions, belching, reflux, fatigue, allergic reactions, and hair loss.

Most of the data on tirzepatide side effects come from 72-week trials. That means they describe what people experienced while taking the medication, not problems that appeared later or lasted after stopping.

So far, though, research shows that tirzepatide is generally well tolerated with long-term use. In a three-year study of people with obesity and prediabetes, digestive symptoms were the most common side effects, and no new major safety concerns emerged. 

Here’s a closer look at the two longest trials:

  • Over three years: In an extension of a 72-week trial, 1,032 adults with obesity and prediabetes continued tirzepatide for a total of three years. Apart from COVID-19 infections, digestive problems were the most common issues reported. Most were mild to moderate and happened in the first 20 weeks, while doses were still going up.

  • Over about four years: A heart health trial followed more than 13,000 adults with type 2 diabetes and plaque-related heart or blood vessel disease for a median of about four years. Digestive problems were more common with tirzepatide than with dulaglutide,* but overall rates of reported health issues appeared similar. Everyone in this trial had type 2 diabetes and heart disease, so the results may not fully apply to people taking tirzepatide for weight loss alone.

However, tirzepatide has only been available since 2022, and the longest trials have lasted about four years. Its effects over decades of treatment remain unknown.

For many people, the benefits of sustained weight loss or better blood sugar control may outweigh the risks. Regular follow-up with your healthcare provider can help spot side effects, check how well the medication is working, and decide whether tirzepatide is still right for you.

*Dulaglutide is a glucagon-like peptide-1 (GLP-1) medication, while tirzepatide acts on receptors for both GLP-1 and a second gut hormone called glucose-dependent insulinotropic polypeptide (GIP).

Which tirzepatide long-term side effects have been reported with ongoing use?

Several side effects, from intestinal and digestive to muscle, hair, and skin issues, have been reported over longer treatment periods in research on tirzepatide or similar medications. These include:

  • Constipation and intestinal problems: In 72-week trials, 11%–17% of people taking Zepbound reported constipation, compared with 5% on placebo. Reports since the drug’s approval also include severe constipation, intestinal blockages, and ileus, a condition in which the intestines slow or stop moving food along.

  • Reflux and indigestion: Gastroesophageal reflux disease, which causes heartburn,affected 4%–5% of people on Zepbound versus 2% on placebo. Indigestion affected 9%–10%, compared with 4%.

  • Fatigue: Between 5% and 7% of people on Zepbound reported feeling tired or weak, compared with 3% on placebo.

  • Muscle and lean mass loss: In a body scan study, people on tirzepatide lost about 11% of their lean mass over 72 weeks. Lean mass accounted for roughly a quarter of the weight drop in both the tirzepatide and placebo groups.

  • Loose skin and facial fat loss: Some clinicians have reported loose skin and facial volume loss with rapid weight loss on GLP-1 medications, a group that includes tirzepatide.

If a side effect bothers you or isn’t going away, let your healthcare provider know. They may suggest a lower maintenance dose if your current one is hard to tolerate.

What are less common but serious long-term risks of tirzepatide?

Gallbladder disease, pancreatitis, kidney injury from dehydration, low blood sugar with certain diabetes medications, and a thyroid tumor warning are among the serious risks listed on tirzepatide’s prescribing label. An FDA warning about a rare eye condition is also being added to tirzepatide and all GLP-1 medications.

Rates of the following serious Zepbound long-term side effects come from two 72-week trials that compared the medication with placebo:

Risk

Zepbound

Placebo

Gallstones

1.1%

1%

Gallbladder inflammation

0.7%

0.2%

Gallbladder removal

0.2%

0%

Acute pancreatitis

0.2%

0.2%

Acute kidney injury

0.5%

0.2%

Severe digestive side effects

1.7%–3.1%

1%

Low blood sugar (type 2 diabetes trial)

4.2%

1.3%

Confirmed pancreatitis was uncommon in clinical trials, but severe cases have been reported in people taking tirzepatide or similar medications.

Most kidney injury reports since approval, in people taking tirzepatide or similar medications, involved dehydration after nausea, vomiting, or diarrhea.

Low blood sugar (hypoglycemia) is more likely when tirzepatide is taken with insulin or sulfonylureas, another type of diabetes medication. In the 72-week trial of people with type 2 diabetes, 4.2% of those taking Zepbound had low blood sugar overall. Zepbound users on a sulfonylurea had a rate of 10.3%, compared with 2.1% for those not on one.

Tirzepatide has also caused thyroid C-cell tumors in rats, though it’s unknown whether it has the same effect in people. Anyone with a personal or family history of medullary thyroid carcinoma (MTC), or an endocrine system condition called multiple endocrine neoplasia syndrome type 2 (MEN 2), shouldn’t use it.

The label also rules out tirzepatide for anyone who’s had a serious allergic reaction to it or any of its ingredients.

In November 2026, the FDA announced a warning about a link between GLP-1–based medications, including tirzepatide, and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). NAION happens when blood flow to the front of the optic nerve drops. It can cause sudden, painless vision loss in one eye, and the vision loss may be permanent. 

In an FDA analysis of 126 clinical trials, NAION occurred in about 6 of every 100,000 people per year of treatment with GLP-1–based medications, compared with about 4 per 100,000 on placebo or other diabetes medications. Diabetes, high blood pressure, sleep apnea, and smoking may raise the risk of NAION.

Contact your healthcare provider right away if you notice:

  • Severe stomach pain that won’t go away, sometimes spreading to your back

  • Upper stomach pain, fever, yellow skin or eyes, or clay-colored stool

  • A lump or swelling in your neck, lasting hoarseness, trouble swallowing, or shortness of breath

  • Nausea, vomiting, or diarrhea that won’t stop

  • Sudden vision loss in one eye, blurry or missing areas of vision, or changes in how colors look

  • Signs of allergic reaction, including swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, a severe rash or itching, fainting or dizziness, or a very fast heartbeat

Is tirzepatide hard on your organs?

Whether tirzepatide is hard on your organs depends on the organ, since it carries some risks for the pancreas, gallbladder, and kidneys, but it may help the kidneys and liver in certain groups, and its effect on the human thyroid is unknown. Here’s what studies show so far:

  • Pancreas: Two pancreatic enzymes, amylase and lipase, rose about 20%–35% on average in the 72-week weight loss trials, compared with small increases on placebo. The label says the meaning of these increases is unknown when there are no other signs of pancreatitis.

  • Gallbladder: Acute gallbladder problems were tied to weight reduction in trials. If gallbladder inflammation is suspected, the label calls for testing and follow-up care.

  • Kidneys: An analysis of people with type 2 diabetes and high heart risk suggests kidney function declined more slowly on tirzepatide than on a daily insulin shot called insulin glargine, over up to two years of treatment.

  • Liver: In a 52-week trial of people with metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease, and moderate or severe liver scarring, the condition resolved without worsening liver scarring in 44%–62% of people on tirzepatide, compared with 10% on placebo. This was an early-stage trial, and tirzepatide isn’t FDA-approved to treat this liver disease.

  • Thyroid: Thyroid C-cell tumors developed in rats given tirzepatide, but whether the same happens in people hasn’t been determined. Routine calcitonin blood tests and neck ultrasounds are of uncertain value for spotting MTC early in people taking tirzepatide, and they may lead to unnecessary procedures.

Much of this organ data comes from trials lasting 1–2 years, so longer studies are needed to show whether these patterns hold over time.

What is still unknown about tirzepatide's long-term safety?

When it comes to tirzepatide’s long-term safety, researchers don’t yet know how the drug affects cancer risk over many years, and some rare side effects may only come up as more people take it. Across tirzepatide trials lasting 26–72 weeks, neither overall cancer risk nor the risk of any specific cancer type went up. But trials of that length can’t show what happens over decades.

The NAION warning shows why that matters. Cases were too rare to show up clearly in individual trials, so the FDA identified the risk by pooling data from more than 100 trials and reviewing real-world studies.

In its first two years on the market, tirzepatide was tied to 37,827 reports in the FDA’s safety reporting database. The most frequent reports were about how the drug was used, such as wrong doses and off-label use, along with injection site pain or bleeding, and nausea. Seven of those reports involved starvation ketoacidosis, a serious condition that stood out as an unexpected safety signal. 

It’s important to note that voluntary reports like these can’t always prove that a drug caused the problem, and 93.9% of tirzepatide’s reports came from consumers rather than healthcare professionals.

Clinicians have also published case reports of three people who developed heart palpitations, muscle or neck and back pain, or headaches after starting tirzepatide or increasing the dose. The authors pointed to these cases as a reason to keep monitoring the drug’s safety after approval.

Separately, the Zepbound label no longer includes a warning about suicidal behavior and ideation. It wasremoved in early 2026 after an FDA review of 91 placebo-controlled studies found no increased risk. If you notice new or worsening mood changes, tell your healthcare provider.

What happens when you stop taking tirzepatide?

A large share of lost weight can come back after people stop taking tirzepatide, and blood pressure and waist size can increase, too.

In a withdrawal trial, 670 adults lost an average of 20.9% of their body weight over 36 weeks on tirzepatide. People who then switched to placebo saw their weight climb 14% over the next 52 weeks, while those who stayed on tirzepatide lost another 5.5%.

Some people did maintain most of their results. After 52 weeks on placebo, 16.6% of those who stopped the medication had kept off at least 80% of the weight they’d lost, compared with 89.5% of those who stayed on tirzepatide. Overall, people who switched to placebo ended up 9.9% below their starting weight, compared with 25.3% for those who stayed on tirzepatide.

People who switched to placebo also saw systolic blood pressure (the top number) rise about eight points, and their waist grow about 3 inches over 52 weeks.

Can you stop tirzepatide cold turkey?

Yes, you can stop taking tirzepatide without gradually lowering your dose first. People in a withdrawal trial switched straight to placebo shots without lowering their dose first. 

Tirzepatide has a half-life of about 5–6 days, which means the amount in your body drops by about half every 5–6 days after your last shot.

Still, don’t stop or lower your dose on your own. Talk to your healthcare provider first, unless they’ve told you to stop because of something like suspected pancreatitis or pregnancy.

If you take tirzepatide for type 2 diabetes, your blood sugar can go up after stopping it, so your provider may need to adjust your other medications.

How can you lower your long-term risk on tirzepatide?

A few daily habits around hydration, muscle maintenance, and regular monitoring can help lower your risk and catch problems early while you take tirzepatide:

  • Protect your muscle. Enough protein and regular strength training are recommended to help preserve muscle and bone during GLP-1 treatment.

  • Stay hydrated. Drinking fluids helps reduce the chance of dehydration, especially if you have nausea, vomiting, or diarrhea. US guidelines suggest adults get about 2.7 to 3.7 liters of water a day from drinks and food, depending on gender (though needs vary with body size, activity, and climate).

  • Keep up with follow-up care. Your healthcare team may check your kidney function if you’re losing fluids from vomiting or diarrhea, monitor your blood sugar if you have diabetes, and check your eyes if you have a history of diabetic retinopathy.

  • Report new symptoms early. Let your healthcare provider know about severe or lasting digestive symptoms. Report sudden vision changes in one eye right away, as well as any vision changes if you have type 2 diabetes.

These habits also fit with how tirzepatide is meant to be used, since the medication is meant to be used with a reduced-calorie diet and more physical activity.

What should you avoid while taking tirzepatide?

A few medications and situations are best avoided while taking tirzepatide:

  • Taking other tirzepatide products or GLP-1 medications at the same time

  • Relying only on birth control pills for four weeks after starting and four weeks after each dose increase

  • Having surgery or sedation without telling your care team you take tirzepatide

  • Taking tirzepatide if you have severe gastroparesis, a condition in which the stomach empties very slowly

  • Using tirzepatide during pregnancy

Tirzepatide slows how quickly your stomach empties. This effect is strongest after the first dose and can make birth control pills less effective. Slower stomach emptying may also raise the risk of complications during anesthesia.

Bottom line

Here’s what the research — including years of trial data and tens of thousands of safety reports — shows about tirzepatide’s long-term safety:

  • Stomach symptoms tend to ease with time. In trials, most nausea, vomiting, and diarrheashowed up while doses were rising and became less frequent afterward.

  • Some serious problems were uncommon in trials. Gallstones, confirmed pancreatitis, and acute kidney injury each affected 1.1% of people or fewer over 72 weeks of treatment, while severe digestive side effects affected up to 3.1%. Low blood sugar was more common in people with type 2 diabetes, affecting 4.2% in one trial.

  • Some risks of tirzepatide are still unknown. Tirzepatide caused thyroid tumors in rats, but it’s unknown whether it does in people. Its effects over decades, including on cancer risk, haven’t been studied yet.

  • Weight can return after stopping tirzepatide. Moving to placebo after 36 weeks on tirzepatide led to an average 14% weight gain over the following year in a withdrawal trial.

  • Muscle needs protecting while taking tirzepatide. In a body scan study, about 25% of weight lost was lean mass (which includes muscle), a similar share to people on placebo. Protein and strength training can help preserve muscle during treatment.

If you’re weighing tirzepatide long-term side effects against the benefits, a Ro healthcare provider can review your health history, prescribe a GLP-1 medication if it’s appropriate, and support you with ongoing care.

Frequently asked questions (FAQs)

DISCLAIMER

If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.

Mounjaro Important Safety Information: Read more about serious warnings and safety info.

Zepbound Important Safety Information: Read more about serious warnings and safety info.

GLP-1 Important Safety Information: Read more about serious warnings and safety info.

References

What’s included

Provider consultation

GLP-1 prescription (if appropriate)

Insurance coverage & paperwork handled

Ongoing care & support

Tools to track progress

Please note: The cost of medication is not included in the Ro Body membership.